Screener Summaries Updates Institutions Sign In More Updates › Other Events › MTVA Other Events · Jun 8, 2026
MetaVia Inc. presented late-breaking data from its obesity and metabolic disease portfolio at the ADA 2026 Scientific… MTVA MetaVia Inc.
MetaVia Inc. presented late-breaking data from its obesity and metabolic disease portfolio at the ADA 2026 Scientific Sessions. The Phase 1 results for DA-1726 showed a 9.1% body weight reduction at Day 54, while preclinical studies for vanoglipel demonstrated significant weight loss and hepatoprotective effects in combination treatments.
More from MetaVia Inc. MetaVia reports 68% placebo-adjusted liver fat reduction and 13.5% weight loss from DA-1726 Phase 1 interim data Nov 5, 2026 MetaVia appoints Sarah Browne, M.D., as Chief Medical Officer Oct 13, 2026 MetaVia Inc. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $5.3… Aug 6, 2026 MetaVia Inc. announced that all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity… Jul 9, 2026 MetaVia Inc. filed a prospectus supplement on July 2, 2026, to offer and sell up to $4,000,000 of common stock under… Jul 2, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
